These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

668 related items for PubMed ID: 24650799

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y, Harashima N, Tajima Y, Harada M.
    Oncotarget; 2015 Dec 08; 6(39):41902-15. PubMed ID: 26506422
    [Abstract] [Full Text] [Related]

  • 23. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
    Iacovelli S, Ricciardi MR, Allegretti M, Mirabilii S, Licchetta R, Bergamo P, Rinaldo C, Zeuner A, Foà R, Milella M, McCubrey JA, Martelli AM, Tafuri A.
    Oncotarget; 2015 Oct 13; 6(31):32089-103. PubMed ID: 26392332
    [Abstract] [Full Text] [Related]

  • 24. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S, Dai Y, Harada H, Dent P, Grant S.
    Cancer Res; 2007 Jan 15; 67(2):782-91. PubMed ID: 17234790
    [Abstract] [Full Text] [Related]

  • 25. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.
    Faber AC, Farago AF, Costa C, Dastur A, Gomez-Caraballo M, Robbins R, Wagner BL, Rideout WM, Jakubik CT, Ham J, Edelman EJ, Ebi H, Yeo AT, Hata AN, Song Y, Patel NU, March RJ, Tam AT, Milano RJ, Boisvert JL, Hicks MA, Elmiligy S, Malstrom SE, Rivera MN, Harada H, Windle BE, Ramaswamy S, Benes CH, Jacks T, Engelman JA.
    Proc Natl Acad Sci U S A; 2015 Mar 17; 112(11):E1288-96. PubMed ID: 25737542
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability.
    Seo BR, Min KJ, Cho IJ, Kim SC, Kwon TK.
    PLoS One; 2014 Mar 17; 9(4):e95588. PubMed ID: 24743574
    [Abstract] [Full Text] [Related]

  • 28. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
    Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B, McQueen T, Bornmann W, Tsao T, Bergamo P, Mak DH, Chen W, McCubrey J, Tafuri A, Andreeff M.
    Leukemia; 2012 Apr 17; 26(4):778-87. PubMed ID: 22064351
    [Abstract] [Full Text] [Related]

  • 29. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
    Risberg K, Redalen KR, Sønstevold L, Bjørnetrø T, Sølvernes J, Ree AH.
    BMC Cancer; 2016 Jul 26; 16():531. PubMed ID: 27461218
    [Abstract] [Full Text] [Related]

  • 30. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
    Goodwin CM, Rossanese OW, Olejniczak ET, Fesik SW.
    Cell Death Differ; 2015 Dec 26; 22(12):2098-106. PubMed ID: 26045046
    [Abstract] [Full Text] [Related]

  • 31. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A.
    Clin Cancer Res; 2007 Dec 01; 13(23):7191-8. PubMed ID: 18056200
    [Abstract] [Full Text] [Related]

  • 32. Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition.
    Coloff JL, Macintyre AN, Nichols AG, Liu T, Gallo CA, Plas DR, Rathmell JC.
    Cancer Res; 2011 Aug 01; 71(15):5204-13. PubMed ID: 21670080
    [Abstract] [Full Text] [Related]

  • 33. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
    Kim A, Park S, Lee JE, Jang WS, Lee SJ, Kang HJ, Lee SS.
    Leuk Res; 2012 Jul 01; 36(7):912-20. PubMed ID: 22560334
    [Abstract] [Full Text] [Related]

  • 34. c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1.
    Campone M, Noël B, Couriaud C, Grau M, Guillemin Y, Gautier F, Gouraud W, Charbonnel C, Campion L, Jézéquel P, Braun F, Barré B, Coqueret O, Barillé-Nion S, Juin P.
    Mol Cancer; 2011 Sep 07; 10():110. PubMed ID: 21899728
    [Abstract] [Full Text] [Related]

  • 35. Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells.
    Mazumder S, Choudhary GS, Al-Harbi S, Almasan A.
    Cancer Res; 2012 Jun 15; 72(12):3069-79. PubMed ID: 22525702
    [Abstract] [Full Text] [Related]

  • 36. Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma.
    Doghman M, Lalli E.
    Mol Cell Endocrinol; 2012 Nov 25; 364(1-2):101-4. PubMed ID: 22960230
    [Abstract] [Full Text] [Related]

  • 37. Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival.
    Eichhorn JM, Alford SE, Sakurikar N, Chambers TC.
    Exp Cell Res; 2014 Apr 01; 322(2):415-24. PubMed ID: 24556425
    [Abstract] [Full Text] [Related]

  • 38. Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein.
    Preuss E, Hugle M, Reimann R, Schlecht M, Fulda S.
    J Biol Chem; 2013 Dec 06; 288(49):35287-96. PubMed ID: 24133218
    [Abstract] [Full Text] [Related]

  • 39. Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.
    Morales AA, Kurtoglu M, Matulis SM, Liu J, Siefker D, Gutman DM, Kaufman JL, Lee KP, Lonial S, Boise LH.
    Blood; 2011 Aug 04; 118(5):1329-39. PubMed ID: 21659544
    [Abstract] [Full Text] [Related]

  • 40. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737.
    Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F, Deb S, Ritchie ME, Takano E, Ward T, Fox SB, Generali D, Smyth GK, Strasser A, Huang DC, Visvader JE, Lindeman GJ.
    Proc Natl Acad Sci U S A; 2012 Feb 21; 109(8):2766-71. PubMed ID: 21768359
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.